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 Abstract Traditional risk charts for the prediction of cardiovascular disease (CVD) include cholesterol 
parameters. We evaluated how models predict fatal CVD when cholesterol is replaced by glucose parameters. 
We used data from NHANES III, a US survey conducted 1988-1994 (follow-up until 2006); 15,454 participants 
(1,716 CVD deaths) were included. Based on the ESC SCORE method, we used age, sex, blood pressure, 
smoking and either of the following: 1) total cholesterol, 2) total-to-HDL-cholesterol, 3) glucose, 4) glycated 
hemoglobin (A1C). Scaled Brier score (BS), Nagelkerke’s R2 (NR) and integrated discrimination improvement 
(IDI) were used for model comparison. The ranking (best to worst) was: A1C (BS=11.62%; NR=0.0865; 
IDI=0.0091), glucose (11.16%; 0.0734; 0.0067), total-to-HDL-cholesterol (9.97%; 0.0547; 0.0010), cholesterol 
(9.75%; 0.0484; 0, reference). Differences between models with cholesterol and glucose or A1C were 
statistically significant. This study suggests the use of A1C instead of cholesterol parameters in charts to assess 
CVD risk. 
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Introduction 
Estimating the individual risk of cardiovascular disease (CVD) is traditionally based on age, sex, smoking status, 
blood pressure and total cholesterol or total-to-HDL-cholesterol. Derived risk prediction models and risk charts 
include the Framingham Risk Score or, from Europe, scores from PROCAM (Prospective Cardiovascular 
Münster Heart Study) or SCORE (Systematic COronary Risk Evaluation) [1] [2] [3]. Based on a large 
population sample from Switzerland with long mortality follow-up, cholesterol parameters contributed only little 
to prediction of mortality risk [4]. Traditional risk scores have been established decades ago. Meanwhile, new 
CVD risk factors have emerged. There is increasing evidence for glucose parameters being independent 
modifiable CVD risk factors [5]. Based on SCORE and adhering to a maximum of five variables displayed in the 
CVD risk chart, we used data from NHANES III to compare the traditional prediction model with models using 
glucose or glycated hemoglobin (A1C) instead of cholesterol.  
 
Methods  
We used data from the US-based NHANES III (Third National Health and Nutrition Examination Survey), 
conducted 1988-1994 and with mortality follow-up until December 31, 2006, originally including 20,050 
individuals [6] (see Web Annex, Table 1). Analysis was restricted to participants with all required variables 
(n=15,454; 1,716 CVD deaths: ICD 9, 390-434; 436-459). We did not explicitly exclude participants with pre-
existing diseases, but we performed sensitivity analyses without persons with known diabetes and/or CVD (see 
Web Annex, Fig. 1 and 2). Risk models were calculated with Weibull proportional hazards regression with age 
as time variable and two strata for sex [1]. Each of the four models included smoking status (binary) and systolic 
blood pressure. As preliminary analyses showed significant deviations from linearity, systolic blood pressure 
was modelled as restricted cubic spline with five knots (at 100, 113, 122, 135, 164 mmHg; see Web Annex, Fig. 
3 and 4). For completion, one of the following variables was additionally included: total cholesterol, total-to-
HDL-cholesterol, glucose, A1C. A final model included both A1C and cholesterol.  
 
To compare the model fit, we used AIC, BIC and a version of Nagelkerke’s R2 by Royston [7]. In order to 
compare the predictive abilities of the models, we calculated the scaled mean cross-validated (leave-one-out) 
Brier score [8] [9] and the integrated discrimination improvement (IDI). A permutation test was used for the 
comparison of Brier scores from different models, and a Wald test was applied in the case of the IDI. The model 
with cholesterol was used as reference. The Brier score measures the mean squared difference between the risk 
score and the actual outcome. The lower this deviation, the better the respective risk prediction model. The Brier 
score covers both calibration, i.e. the agreement of the prediction with the true predictive distribution, and 
sharpness, i.e. the precision of the predictive distribution. The IDI is a measure of improvement in model 
performance and represents the difference in discrimination slopes of the competing models.  
 
Analyses were performed with STATA 11 (Stata Corp, Texas, USA, 2009) and R (R Foundation for Statistical 
Computing, version 2.14.1).  
 
Results 
The predictive capacity of cholesterol and total-to-HDL-cholesterol was not significantly different (Table 1). 
Including cholesterol in addition to A1C did not improve the predictions. Risk charts derived from the analyses 
are shown in Fig. 1 and 2. The A1C chart much better discriminated individuals with high and low CVD risk. 
Based on A1C and cholesterol, respectively, 11.8% and 11.2% of the study population had a high CVD risk 
(≥20%). Glucose and A1C predicted mortality significantly better than cholesterol even after exclusion of 
persons with known diabetes or CVD (Web Annex, Fig. 1 and 2). 
 
Discussion 
Our comparisons based on data from NHANES III suggest using A1C instead of cholesterol for CVD mortality 
risk charts. As shown by others, A1C not only serves as a predictor of diabetes, it has also the ability to predict 
death from CVD and from any cause and its predictiveness was better than that of glucose [5]. Traditional risk 
models do not consider glucose parameters as continuous variable. The PROCAM and the Framingham models 
include information about diabetes (yes/no) [2] [3] but this does not sufficiently map the potential impact of 
blood glucose on CVD. With dichotomization, mortality gradients below the threshold for diabetes are missed, 
which wastes prevention potential. In fact, excluding individuals with known diabetes only marginally attenuated 
absolute risks (see Web Annex, Fig. 1), suggesting that the A1C chart could also be used for primary prevention. 
Mortality risk increases at A1C concentrations ≥5.7%. This threshold is lower when other CVD risk factors, e.g. 
high blood pressure or smoking, are present [5] [10]. This is also suggested by the risk chart derived from our 
analyses (Fig. 1).  
 
One advantage of considering A1C in a continuous (instead of a dichotomized) form is that the CVD risk chart 
could be a tool for physicians helping to prevent or delay the onset of diabetes in persons with prediabetes (A1C 
5.7-6.4%) potentially reducing morbidity and premature death. The chart could be used to motivate individuals 
to follow lifestyle recommendations and to improve compliance. A1C can be lowered with physical activity, 
weight management and healthy diet and, thus, opens doors for lifestyle recommendations [11] [12]. Prediabetes 
can also be effectively treated with Metformin which decreases the rate of conversion from prediabetes to 
diabetes [11]. Caring for persons early in the pathway to diabetes may be much more effective than treating them 
once diabetes is established. This is not possible when the risk associated with increased A1C concentrations is 
only considered dichotomously. A1C can easily and inexpensively be measured and also be interpreted in the 
non-fasting state [5], thus facilitating screening procedures. Our analyses do not suggest that additional 
assessment of cholesterol parameters is necessary for risk assessment. In contrast, relying on cholesterol 
parameters only could mean to miss persons with increased CVD risk. In hypercholesterolemic patients, CVD 
mortality could further be reduced with management of A1C [10]. This is also suggested when comparing the 
respective risk charts. However, whether reduction in A1C leads to a similar reduction in CVD as with 
improvement of cholesterol parameters (by lifestyle modification or medication) remains to be elucidated.  
We conclude that CVD risk assessment including A1C may be superior to the traditional CVD risk chart with 
cholesterol. This needs to be confirmed with other populations.  
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 Table 1. Estimated coefficients of modifiable risk factors of selected models with comparison measures 
 
             
 
Chart Models (5 variables) 
 
Separate Model (6 variables) 
  Total Cholesterol Total-to-HDL-cholesterol Glucose A1C  A1C + total cholesterol 
Current smoking (yes/no) 1.994 (1.760; 2.260) 1.990 (1.756; 2.255) 2.046 (1.806; 2.318) 2.011 (1.775; 2.279) 2.010 (1.774; 2.278) 
Total Cholesterol (mmol/L) 1.058 (1.013; 1.104) 1.045 (1.001; 1.090) 
Total-to-HDL-cholesterol (ratio) 1.073 (1.045; 1.102) 
Glucose (mmol/L) 1.087 (1.070; 1.105) 
Glycated hemoglobin (A1C, %) 1.226 (1.186; 1.267) 1.223 (1.184; 1.264) 
Model comparison 
Scaled mean Brier Score 9.75% 9.97% 11.16% 11.62% 11.65% 
Nagelkerke's R^2 0.0484 0.0547 0.0734 0.0865 0.0879 
AIC 2075 2057 2003 1965 1963 
BIC 2152 2133 2079 2041 2047 
Integrated discrimination improvement (IDI) 0 (reference) 0.0010 (0.16) 0.0067 (<0.001) 0.0091 (<0.001)  0.0089 (<0.001) 
 
 
Hazard ratios; figures in brackets are 95% confidence intervals (coefficients) or p-values (model comparison). Blood pressure was included as a restricted cubic spline with five knots (100, 113, 122, 
135, 164 mmHg); see Fig. A1 and A2 in the Web Annex.  
 Figure Legends 
 
Fig. 1. Chart for absolute 10-year risk of fatal cardiovascular disease based on the model using A1C, 
15,454participants of the NHANES III study, 1988-1994 
Age
180 17 20 24 29 34 31 37 43 50 57 22 26 31 37 43 39 46 53 60 68
160 15 18 21 25 30 27 32 38 44 51 19 23 27 32 38 35 41 47 54 62
140 13 16 19 23 27 25 29 35 41 47 17 21 25 29 35 31 37 43 50 57
120 13 15 18 22 26 24 28 34 40 46 17 20 24 28 34 31 36 42 49 56
180 9 11 13 16 19 17 21 25 30 35 13 16 19 23 28 25 30 35 41 48
160 8 9 11 14 17 15 18 22 26 31 11 14 17 20 24 22 26 31 36 42
140 7 8 10 12 15 13 16 20 23 28 10 12 15 18 22 20 23 28 33 39
120 7 8 10 12 15 13 16 19 23 27 10 12 15 18 21 19 23 27 32 38
180 5 6 7 8 10 9 11 13 16 19 8 9 11 14 16 15 18 21 25 30
160 4 5 6 7 9 8 9 11 14 16 7 8 10 12 14 13 15 18 22 26
140 3 4 5 6 8 7 8 10 12 15 6 7 9 10 13 11 14 17 20 24
120 3 4 5 6 7 7 8 10 12 14 6 7 8 10 12 11 13 16 19 23
180 2 3 3 4 5 4 5 6 8 9 4 5 6 7 9 8 10 12 14 17
160 2 2 3 3 4 4 4 5 7 8 4 4 5 6 8 7 8 10 12 15
140 2 2 2 3 4 3 4 5 6 7 3 4 5 6 7 6 8 9 11 13
120 2 2 2 3 4 3 4 5 6 7 3 4 5 6 7 6 7 9 11 13
180 1 1 1 2 2 2 2 3 3 4 2 3 3 4 5 4 5 6 8 9
160 1 1 1 1 2 2 2 2 3 4 2 2 3 3 4 4 4 5 6 8
140 1 1 1 1 2 1 2 2 3 3 2 2 2 3 4 3 4 5 6 7
120 1 1 1 1 2 1 2 2 3 3 2 2 2 3 3 3 4 5 6 7
180 0 0 1 1 1 1 1 1 1 2 1 1 2 2 2 2 2 3 4 5
160 0 0 0 1 1 1 1 1 1 1 1 1 1 2 2 2 2 3 3 4
140 0 0 0 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 3 3
120 0 0 0 1 1 1 1 1 1 1 1 1 1 1 2 1 2 2 3 3
5 6 7 8 9 5 6 7 8 9 5 6 7 8 9 5 6 7 8 9
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NHANES III: Third National Health and Nutrition Examination Survey; Each risk percentage is calculated using 
a combination of given risk factor values. E.g., a man aged 65, smoker, with a systolic blood pressure of 180 and 
a A1C of 9% has an absolute risk (within the next 10 years) of fatal CVD of 29%. 
 Fig. 2. Chart for absolute 10-year risk of fatal cardiovascular disease based on the model using total cholesterol, 
15,454participants of the NHANES III study, 1988-1994 
Age
180 18 19 20 21 22 33 34 36 38 39 24 25 27 28 29 42 44 46 48 50
160 16 16 17 18 19 29 30 32 33 35 21 22 23 24 25 37 39 41 43 44
140 14 15 16 16 17 26 27 29 30 31 19 20 21 22 23 34 36 37 39 41
120 14 14 15 16 17 25 26 28 29 30 18 19 20 21 22 33 35 36 38 39
180 10 10 11 12 12 19 20 21 22 23 15 16 16 17 18 27 29 30 31 33
160 8 9 9 10 10 16 17 18 19 20 13 13 14 15 16 24 25 26 27 29
140 8 8 8 9 9 15 15 16 17 18 11 12 13 13 14 21 23 24 25 26
120 7 8 8 9 9 14 15 16 16 17 11 12 12 13 14 21 22 23 24 25
180 5 5 6 6 6 10 10 11 11 12 9 9 9 10 11 16 17 18 19 20
160 4 5 5 5 5 8 9 9 10 10 7 8 8 9 9 14 15 16 16 17
140 4 4 4 5 5 8 8 8 9 9 7 7 7 8 8 13 13 14 15 16
120 4 4 4 4 5 7 8 8 9 9 6 7 7 7 8 12 13 13 14 15
180 2 3 3 3 3 5 5 5 6 6 5 5 5 5 6 9 10 10 11 11
160 2 2 2 2 3 4 4 5 5 5 4 4 4 5 5 8 8 9 9 10
140 2 2 2 2 2 4 4 4 4 5 4 4 4 4 4 7 7 8 8 9
120 2 2 2 2 2 4 4 4 4 4 3 4 4 4 4 7 7 7 8 8
180 1 1 1 1 1 2 2 2 3 3 2 3 3 3 3 5 5 5 6 6
160 1 1 1 1 1 2 2 2 2 2 2 2 2 2 3 4 4 4 5 5
140 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 4 4 4 4 4
120 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 4 4 4 4
180 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 3 3 3
160 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2
140 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2
120 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
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NHANES III: Third National Health and Nutrition Examination Survey; Each risk percentage is calculated using 
a combination of given risk factor values. E.g., a man aged 65, smoker, with a systolic blood pressure of 180 and 
a total cholesterol of 8 mmol/L has an absolute risk (within the next 10 years) of fatal CVD of 19%. 
 
